Patents by Inventor Kwee Yong

Kwee Yong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimeric Antigen Receptor
    Publication number: 20240076352
    Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising: (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.
    Type: Application
    Filed: May 22, 2023
    Publication date: March 7, 2024
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Ben Draper
  • Bi-specific T-cell engager specific for BCMA
    Patent number: 11492408
    Abstract: The present invention provides a bi-specific molecule which comprises: (i) a first domain which binds B cell maturation antigen (BCMA) and comprises at least part of a proliferation-inducing ligand (APRIL); and (ii) a second domain capable of activating a T cell. The invention also provides the use of such a molecule in the treatment of plasma-cell mediated diseases, such as multiple myeloma.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: November 8, 2022
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Neil Chaplin
  • CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20210101959
    Abstract: The present invention provides a chimeric antigen recept- or (CAR) comprising: (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.
    Type: Application
    Filed: October 22, 2020
    Publication date: April 8, 2021
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Ben Draper
  • Chimeric antigen receptor
    Patent number: 10919951
    Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising; (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: February 16, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Ben Draper
  • April variants
    Patent number: 10752665
    Abstract: The present invention provides a variant proliferation-inducing ligand (APRIL) which has a higher binding affinity to BCMA than wild-type APRIL; and/or altered binding kinetics compared with wild-type APRIL, and/or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations at one or more of the following positions: A125, V174, T175, M200, P201, S202, H203, D205 and R206.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: August 25, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Neil Chaplin, Ben Draper
  • Ligand
    Patent number: 10611811
    Abstract: The present invention provides a variant proliferation-inducing ligand (APRIL), which has a higher binding affinity to BCMA than wild-type APRIL; and/or altered binding kinetics compared with wild-type APRIL, and/or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations at one or more of the following positions: A125, V174, T175, M200, P201, S202, H203, D205 and R206.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: April 7, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Neil Chaplin, Ben Draper
  • CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20190100571
    Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising; (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.
    Type: Application
    Filed: October 17, 2018
    Publication date: April 4, 2019
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Ben Draper
  • Chimeric antigen receptor
    Patent number: 10160794
    Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising: (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: December 25, 2018
    Assignee: UCL BUSINESS PLC
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Ben Draper
  • Ligand
    Publication number: 20170334964
    Abstract: The present invention provides a variant proliferation-inducing ligand (APRIL), which has a higher binding affinity to BCMA than wild-type APRIL; and/or altered binding kinetics compared with wild-type APRIL, and/or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations at one or more of the following positions: A125, V174, T175, M200, P201, S202, H203, D205 and R206.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 23, 2017
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Neil Chaplin, Ben Draper
  • APRIL VARIANTS
    Publication number: 20160362467
    Abstract: The present invention provides a variant proliferation-inducing ligand (APRIL), which has a higher binding affinity to BCMA than wild-type APRIL; and/or altered binding kinetics compared with wild-type APRIL, and/or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations at one or more of the following positions: A125, V174, T175, M200, P201, S202, H203, D205 and R206.
    Type: Application
    Filed: February 26, 2015
    Publication date: December 15, 2016
    Applicant: UCL Business PLC
    Inventors: Martin PULE, Kwee YONG, Lydia LEE, Neil CHAPLIN, Ben DRAPER
  • CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20160237139
    Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising: (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.
    Type: Application
    Filed: October 10, 2014
    Publication date: August 18, 2016
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Ben Draper